Fluclotizolam (Item No. 23524) is an analytical reference standard categorized as a thienotriazolodiazepine. This product is intended for research and forensic applications.
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H- [1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a triazolobenzodiazepine and is structurally similar to alprazolam. Flualprazolam is composed of a benzene ring fused to a seven-membered 1,4- diazepine ring. Flualprazolam also contains a fused triazolo ring. A methyl (-CH3) group is attached at the 1-position, a 2- fluorophenyl ring is attached at the 6-position, and a chlorine is attached at the 8-position of the triazolobenzodiazepine structure. Flualprazolam has a molecular formula of C17H12ClFN4 and a molecular weight of 326.76 g/mol.
Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.
Fluclotizolam is one of the New Psychoactive Substancces (NPS).
Fluclotizolam produces a sedative-hypnotic effect, often causing drowsiness, muscle relaxation and slowed, sluggish reactions.
1. Moosmann, B., and Auw?rter, V. New Psychoactive Substances. Handbook of Experimental Pharmacology. Designer benzodiazepines: Another class of new psychoactive substances 252, 383-410 (2018).
